Multiple Sclerosis & Neuroimmunology Program
520 Superior, Suite 350, Newport Beach, CA 92663
(949) 764-1850
- About
- Diagnosis
- Treatments
- Advances in MS Care
- Multiple Sclerosis Hope Center
- Meet the Team
- FAQs
MS Care
Advancing the Future of MS Care Through Innovation
Thanks to the generosity of the Hoag Foundation Innovators Fund for Research, Dr. Yasir Jassam and the Hoag MS & Neuroimmunology Program are leading the way in redefining how multiple sclerosis (MS) is diagnosed, treated, and even predicted. Dr. Jassam takes a three-pronged approach that combines the latest technology with forward-thinking research to improve the lives of people living with MS:
Improving Precision Medicine
Every person with MS experiences the disease differently, which is why personalized care is so important. At Hoag, patients benefit from advanced tools like the Octave blood test—a first in Southern California—that can determine the stage of disease, and ICOMETRIX MRI technology, which can reveal hidden signs of chronic active MS that standard scans often miss. By identifying the “central vein sign,” these scans help distinguish MS from other brain conditions, reducing the risk of misdiagnosis and ensuring patients get the right treatment sooner.
A View Into the Future
Hoag is one of the select sites actively testing new therapies that aim to change the course of MS. Current clinical trials include medications for both relapsing and progressive forms of the disease, such as Remibrutinib (REMODEL-2) and Frexalimab (FREVIVA). These studies open doors to treatment options that may not be available anywhere else and give patients early access to therapies that could improve their long-term outcomes.
Predicting and Preventing MS Before It Starts
In an ambitious effort to stop MS before symptoms appear, Dr. Jassam is developing a Risk Index for MS (RIMS)—a scoring system that combines genetics, environment, lifestyle, and other known risk factors. When paired with blood biomarkers, this tool could identify individuals at high risk for developing MS, offering the possibility of early intervention years before the disease takes hold.
Together, these initiatives reflect Dr. Jassam’s bold vision: treat MS early, treat it aggressively when appropriate, and tailor care to each individual so they can achieve No Evidence of Disease Activity (NEDA)—the best possible outcome for patients today, and a brighter future for tomorrow.
Stay up-to-date on the latest news from Hoag
By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.







